RxDoctor Payments Data

John Tabacco, MD

Internal Medicine · Washington, DCNPI 1437443330

Payments from drug & device makers

$1,691in general payments, 2019–2025

Across 79 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$316
  • AbbVie$281
  • Amgen$238
  • Pfizer$164
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$69
  • Astellas Pharma US Inc$68
  • plus $555 from 16 others

What the payments were for

  • Food & beverage$1,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,691 in reported general payments places this provider in the 80th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$119,030
Medicare patients
380
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$130,287
FarxigaDapagliflozin Propanediol39$42,397
OzempicSemaglutide38$33,623
MounjaroTirzepatide27$27,591
XareltoRivaroxaban34$22,900
JanuviaSitagliptin Phosphate17$16,629
NexletolBempedoic Acid11$9,503
SynthroidLevothyroxine Sodium78$7,005
Rosuvastatin Calcium260$5,483
Breo ElliptaFluticasone/Vilanterol12$4,727
Levothyroxine Sodium242$4,469
Losartan Potassium237$3,349
Metoprolol Succinate136$3,073
Escitalopram Oxalate142$2,906
PaxlovidNirmatrelvir/Ritonavir63$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$164$133,146178 claims
Novo NordiskOzempic$316$33,62338 claims
Lilly USA, LLCMounjaro$52$27,59127 claims
Esperion Therapeutics, Inc.Nexletol$40$9,50311 claims
AbbVieSynthroid$281$7,00578 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →